Monograph Details
|
|
Hematology
> Thromboembolic disorders
|
|
INNOHEP |
| Manufacturer |
|
Celgene Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Low molecular weight heparin. |
| Generic Name |
|
Tinzaparin sodium 20000 anti-Factor Xa IU; per mL; for deep SC inj; contains sulfites and benzyl alcohol. |
| Indications |
|
With warfarin: treatment of acute symptomatic DVT with or without pulmonary embolism. |
| Children |
|
Not recommended. |
| Adults |
|
Give by deep SC inj into abdominal wall; rotate inj sites. 175 IU/kg once daily for 6 days until adequately anticoagulated with warfarin (INR ≥2 for two consecutive days). Start warfarin within 1–3 days. |
| Contraindications |
|
Active major bleeding. History of or active heparin-induced thrombocytopenia. Heparin or pork allergy. |
| Precautions |
|
Neuraxial anesthesia and post-op indwelling epidural catheter or spinal puncture (risk of epidural or spinal hematoma). Bleeding disorders. Bacterial endocarditis. Uncontrolled hypertension. Active ulceration and angiodysplastic GI disease. Hemorrhagic stroke. Recent brain, spine, or eye surgery. Bleeding diathesis. Recent history of GI ulcer. Diabetic retinopathy. Thrombocytopenia (discontinue if platelet count <100000/mm3 occurs). Severe renal impairment. Monitor CBC and for occult blood in stool. Not interchangeable (unit-for-unit) with heparin or other low molecular weight heparins. Asthma. Elderly. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Caution with drugs that affect hemostasis (eg, oral anticoagulants, platelet inhibitors including salicylates, NSAIDs, dipyridamole, sulfinpyrazone). |
| Adverse Reactions |
|
Hemorrhage, thrombocytopenia, elevated aminotransferases, inj site reactions (e.g., hematoma), chest pain, headache, GI upset, fever, pain, rash. |
| How Supplied |
|
Vials (2mL)—1, 10 |
|
|
|
|
